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ABSTRACT	
Detection	of	intracerebral	targets	with	imaging	probes	is	challenging	due	to	the	non-
permissive	nature	of	blood-brain	barrier	(BBB).	The	present	work	describes	two	novel	single-
domain	antibodies	(VHHs	or	nanobodies)	that	specifically	recognize	extracellular	amyloid	
deposits	and	intracellular	tau	neurofibrillary	tangles,	the	two	core	lesions	of	Alzheimer’s	
disease	(AD).	Following	intravenous	administration	in	transgenic	mouse	models	of	AD,	in	
vivo	real-time	two-photon	microscopy	showed	gradual	extravasation	of	the	VHHs	across	the	
BBB,	diffusion	in	the	parenchyma	and	labeling	of	amyloid	deposits	and	neurofibrillary	tangles.	
Our	results	demonstrate	that	VHHs	can	be	used	as	specific	BBB-permeable	probes	for	both	
extracellular	and	intracellular	brain	targets	and	suggest	new	avenues	for	therapeutic	and	
diagnostic	applications	in	neurology.	
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1. Introduction	
Brain	penetration	of	targeted	compounds,	such	as	high	affinity	antibodies,	is	a	prerequisite	
for	the	treatment	and	diagnosis	of	central	nervous	system	pathologies.	However,	the	entry	
into	the	central	nervous	system	of	most	of	blood-circulating	molecules	is	seriously	limited	by	
the	blood-brain	barrier	(BBB).	It	has	been	shown	that	only	0.02%	-	0.1%	of	conventional	
immunoglobulins	present	in	serum	can	penetrate	into	brain	parenchyma	[1,2].	Hijacking	the	
BBB	receptor-mediated	transcytosis	system	has	been	envisioned	as	a	way	of	promoting	
passage	of	agents	in	the	brain.	Antibodies	directed	against	the	transferrin	receptor	[3],	or	
the	insulin	receptor	[4]	have	hence	been	used	as	Trojan	horses	to	transport	therapeutic	
molecules	across	the	BBB.	Unfortunately,	receptor-mediated	transcytosis	targets	are	highly	
and	broadly	expressed	in	tissues	and	are	often	implicated	in	critical	cellular	functions,	
therefore	raising	possible	safety	risks	[5,6].	Artificial	BBB	opening	by	ultrasound	[7,8]	or	by	
means	of	BBB	permeability	enhancers	(e.g.	mannitol	[9])	is	also	an	option	to	facilitate	the	
penetration	of	compounds	within	the	brain	but	these	methods	also	have	safety	limitations	
[10].	
Another	approach	of	targeting	intracerebral	epitopes	relies	on	the	use	of	homodimeric	
heavy	chain-only	antibodies	naturally	produced	in	camelidae	[11].	These	“non-conventional”	
single-domain	antibodies	are	devoid	of	light	chains	and	their	heavy	chain	variable	domain	
(VHH)	acts	as	a	fully	functional	binding	moiety	[12].	VHHs	have	several	unique	features	such	
as	relatively	low	molecular	weight,	high	production	yield,	high	stability	and	solubility	with	
the	ability	to	specifically	bind	target	epitopes	at	subnanomolar	affinity.	Due	to	their	small	
size	(15	kDa),	VHHs	occupy	only	1/10	of	the	volume	filled	by	conventional	antibodies	[11].	
Consequently,	they	can	diffuse	more	rapidly	and	deeply	in	fixed	tissues	[13]	and	have	a	
better	biodistribution	profile	in	vivo	than	conventional	antibody	fragments	[14,15].	
Depending	on	their	binding	properties,	VHHs	can	be	used	either	to	visualize	and/or	to	
interact	with	intracellular	targets	[16–22].	
We	recently	demonstrated	that	some	VHHs	with	a	basic	isoelectric	point	(pI)	are	able	to	
readily	transmigrate	across	the	BBB	in	vivo	after	peripheral	injection,	without	the	need	of	
any	invasive	or	hazardous	procedures	(such	as	opening	of	the	barrier	using	chemical	or	
ultrasound	sonication)	[18].	These	VHHs	can	be	used	as	specific	transporters	as	
demonstrated	by	in	vivo	labeling	of	astrocytes	with	a	VHH-fluorophore	conjugate	targeting	
the	intracellular	protein	GFAP	[18].	
In	the	present	work	we	engineered	two	new	VHHs	that	were	able	to	detect	extracellular	or	
intracellular	pathological	brain	targets,	namely	the	two	main	neuropathological	lesions	in	
Alzheimer’s	disease	(amyloid	plaques	and	neurofibrillary	tangles	-	NFTs).	We	designed	
sensitive	and	specific	anti-Aβ	and	anti-tau	VHHs	that	allowed	detection	of	plaques	and	NFTs	
in	brain	tissue	from	patients	with	Alzheimer’s	disease	and	from	mouse	models	of	the	disease.	
We	also	showed	that	plaques	and	tangles	could	be	visualized	in	vivo	in	mice	following	
intravenous	administration	of	these	probes.	
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2. Materials	and	methods	
The	main	experimental	procedures	are	described	here.	Detailed	materials	and	methods	are	
provided	in	Supplementary	Materials.	
2.1. 	Human	AD	brain	extracts	and	immunization		
A	male	alpaca	was	immunized	with	1mg	of	fibrillar	synthetic	Aβ 42	peptide	(Bachem).		
One	alpaca	was	immunized	with	tangles-enriched	AD	extracts	(Braak	stage	V	and	VI)	that	
were	obtained	from	the	NeuroCEB	brain	bank.	This	bank	is	associated	to	a	brain	donation	
program	run	by	a	consortium	of	patient	associations	(including	France	Alzheimer	
Association)	and	declared	to	the	Ministry	of	Research	and	Universities,	as	requested	by	
French	Law.	An	explicit	written	consent	was	obtained	for	the	brain	donation	in	accordance	
with	the	French	Bioethical	Laws.	Another	alpaca	was	immunized	with	a	synthetic	mono-
phosphorylated	peptide	derived	from	the	C-terminus	of	the	tau	protein.	A	detailed	
description	is	provided	in	Supplementary	Materials.	
2.2. Library	construction,	phage	preparation	and	phage	display	
The	library	construction	was	described	in	[23].	Phages	were	prepared	by	transformation	of		
E.coli	host	cells	with	a	recombinant	phagemid	and	a	helper	phage.	A	large	number	of	phages	
(1013)	and	different	blocking	buffers	were	used	to	perform	each	round	of	phage-display.	A	
complete	description	is	provided	in	Supplementary	Materials.	
2.3. Selection	of	specific	phage-VHHs	and	binding	epitope	
determination	of	monoclonal	phage-VHH	
The	libraries	of	anti-Aβ	and	anti-pTau	VHHs	were	panned	for	reactivity	with	biotinylated		
Aβ42,	Aβ40	peptides	and	full-length	pTau	protein	respectively.	Epitope	mapping	of	Aβ	
specific	VHHs	was	performed	by	the	ELISA	inhibition	test.	A	detailed	protocol	is	provided	in	
Supplementary	Materials.	
2.4. Expression	of	VHHs	
The	coding	sequences	of	the	selected	VHHs	(R3VQ	and	A2)	in	the	vector	pHEN1	were	sub-
cloned	into	a	bacterial	expression	vector	pET23d	(Novagen)	containing	a	6-Histidine	tag	
using	NcoI	and	NotI	restriction	sites.	Purified	VHHs	were	isolated	from	transformed	E.	coli	
BL21	(DE3)	pLysS	cells	by	immobilized-metal	affinity	chromatography	(IMAC).	The	full	
method	is	described	in	Supplementary	Materials.	
2.5. Determination	of	pI	by	IsoElectric	Focusing	(IEF)	
The	pI	of	VHHs	was	determined	by	isoelectric	focusing	using	IEF	3-10	Gel	(Invitrogen).	
NEPGHE	(non	equilibrium	pH	gradient	gel	electrophoresis)	with	sample	application	at	the	
anode	was	also	used	because	it	allows	optimal	protein	analysis	in	the	basic	range	of	the	gel	
including	pI	8.5	to	10.5	(SERVA	Gel	IEF	3-10	instruction	manual).	
2.6. Preparation	of	AlexaFluor	488-conjugated	VHH	and	mAb	
The	cysteine	present	in	the	C-terminal	region	of	VHH	and	the	SH	group	in	the	hinge	region	of	
reference	mAbs	(4G8	and	muRb86)	were	used	to	realize	the	conjugation	with	the	
maleimido-AF488	fluorophore	(Invitrogen).	A	detailed	description	is	provided	in	
Supplementary	Materials.		
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2.7. Animal	models	
PS2APP	mice	overexpressing	hAPP	Swedish	mutation	combined	with	PS2	N141I	mutation		
[24,25]	were	used	as	animal	models	harboring	Aβ-positive	lesions.	PS2APP	mice	start	to	
develop	overt	Aβ	deposition	in	the	brain	at	approximately	6	months	of	age.		
Tg4510	mice	with	the	hMAPT	P301L	gene	mutation	[26]	were	used	as	NFT-bearing	mouse	
model.	NFT	start	to	appear	in	the	cortex	by	4	months	of	age	and	one	month	later	in	the	
hippocampus.	All	animal	experiments	were	performed	in	accordance	with	the	guidelines	
established	by	European	Union	legislation	regarding	the	use	and	care	of	laboratory	
animals.	Four	PIs	of	the	present	study	(B.	D.,	Pi.L.,	M.V.	and	M.D.)	have	received	official	
agreements	from	the	French	Ministry	of	Agriculture	to	carry	out	research	and	
experiments	on	animals.	
2.8. Stereotaxic	injections	of	VHHs	
Stereotaxic	injections	of	each VHH	were	performed	in	anesthetized	mice.	Two	microliters	of	
VHH	was	injected	into	the	frontal	cortex	at	the	rate	of	0.2µl	/min.	Two	or	24	hours	later,	
brains	were	collected	for	histological	analysis.	A	detailed	protocol	is	provided	in	
Supplementary	Materials.	
2.9. Immunohistochemistry	and	double	immunofluorescence	
staining		
Immunohistochemistry	was	primarily	performed	on	4μm	thick	paraffin	sections.	A	pre-
treatment	with	formic	acid	was	performed	before	neutralization	of	endogenous	peroxidase	
activity.	After	incubation	with	primary	and	secondary	antibodies	(see	Supplementary	
Materials),	standard	immuno-peroxydase	method	was	applied	with	DAB	as	final	chromogen.	
Immunohistochemistry	on	free-floating	sections,	fresh	tissues	and	VHH-exposed	tissues	was	
performed	with	similar	procedures.	Double	immunofluorescence	staining	was	implemented	
on	paraffin	sections	using	standard	protocols.	A	detailed	description	is	provided	in	
Supplementary	Materials.	
2.10. Estimation	of	lesion	loads	by	VHHs	and	reference	antibodies	
Comparative	lesion	loads	detected	by	VHHs	vs	reference	antibodies	were	assessed	on	
immunostained	sections	obtained	from	PS2APP	and	Tg4510	mice.	The	full	method	is	
described	in	Supplementary	Materials.	
2.11. Intravenous	administration	of	AF488-conjugated	VHH	and	
monoclonal	antibodies	
AlexaFluor	conjugated	VHH	was	slowly	injected	into	the	caudal	vein	of	the	AD	mice.	Two-
photon	imaging	was	then	performed	during	the	2-4	subsequent	hours.	For	control	
experiments	relying	on	peripheral	injections	with	no	in	vivo	imaging,	the	same	procedures	
were	applied	but	no	cranial	surgery	was	performed.	A	detailed	protocol	is	provided	in	
Supplementary	Materials.	
2.12. In	vivo	two-photon	imaging		
Mice	were	anesthetized.	Their	head	was	immobilized	and	a	small	craniotomy	was	performed	
above	the	right	hemisphere.	A	detailed	description	of	the	craniotomy	surgery	is	provided	in	
Supplementary	Materials.	Two-photon	imaging	was	performed	with	a	two-photon	laser-
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scanning	microscope	system	and	PrairieView	software	(Prairie	Technologies,	Middelton,	WI),	
using	a	16x	0.8	NA	water	immersion	objective	(Nikon,	Tokyo,	Japan)	with	the	two-photon	
laser	tuned	to	920	nm	(MaiTai	DeepSee,	Spectra	Physics,	Mountain	View,	CA).	The	images	
were	acquired	at	512	x	512	with	a	pixel	size	of	0.5	um.	Care	was	taken	to	use	less	than	20	
mW	of	laser	power	in	the	tissue.	The	raw	data	obtained	were	processed	using	Image	J	
software	for	analysis	and	3D	rendering.	
	
3. RESULTS	
3.1. Selection	and	characterization	of	a	VHH	recognizing	
extracellular	targets	
3.1.1. Generation	and	optimization	of	R3VQ		
One	alpaca	was	immunized	with	a	fibrillar	synthetic	Aβ42	peptide	and	a	specific	VHH	library	
was	constructed	from	cDNA	encoding	VHH	domains	isolated	from	lymphocytes.	The	total	
size	of	the	library	contained	1x	108	phage-VHHs.	VHHs	were	selected	by	Phage	Display	
through	3	panning	cycles	with	biotinylated	Aβ42	and	Aβ40	peptides	at	different	
concentrations	of	antigens,	buffer	and	washing	conditions.	Four	hundreds	individual	clones	
were	tested	by	ELISA	using	biotinylated	Aβ42.	Two	VHHs	were	obtained,	called	R3VQ	and	
R3VE	respectively.	They	differed	by	only	one	amino	acid:	a	glutamine	(Q)	of	R3VQ	was	
replaced	by	a	glutamic	acid	(E)	in	R3VE.	R3VQ	recognized	an	epitope	located	in	the	central	
part	of	the	Aβ	peptide	between	aa	17-28	(Fig.	S1A).	
C	terminal	His	tagged	VHH	R3VQ	and	R3VE	were	obtained	after	subcloning	of	their	genes	in	
pET23d	vector.	Both	VHHs	had	high	production	yields	about	20	and	9mg/l	of	culture,	
respectively.	Note	that	in	the	present	study,	R3VQ	and	R3VE	represent	R3VQ-His	and	R3VE-
His	antibodies	unless	otherwise	mentioned.	As	a	basic	pI	favors	BBB	passage	[18],	we	decided	
to	focus	our	study	on	R3VQ,	which	had	a	higher	pI	than	R3VE	(see	below).	R3VQ	showed	good	
purity	with	only	one	band	observed	by	SDS-PAGE	(Fig.	1A).	It	had	a	basic	pI	>	8.3	(Fig.	1B).	By	
ELISA,	R3VQ	showed	strong	binding	to	Aβ40	and	Aβ42	(Fig.	1C).	
	
	
	
Fig.	1.	Biochemical	characterization	of	R3VQ	and	its	variants.		
(A)	Analysis	of	R3VQ	variants	by	SDS-PAGE.	(B)	Determination	of	pI	of	R3VQ	variants	by	
NEPHGE	on	3-10	IEF	gel.	(C)	Binding	of	purified	R3VQ	to	biotinylated	Aβ40	and	42	determined	
by	ELISA.	
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We	engineered	a	fluorescent	conjugate	to	allow	in	vivo	imaging	with	microscopic	resolution.	
For	this	purpose,	an	additional	cysteine	residue	was	inserted	in	the	C	terminal	part	of	the	
sequence	of	R3VQ	(referred	as	R3VQ-SH),	thus	allowing	a	C	terminal	thio-addition	of	a	
maleimido-Alexa	fluor	dye	(AF488)	by	a	site	specific	approach	[27].	The	coding	sequence	of	
R3VQ-SH	contained	a	N-terminal	6-histidine	tag	for	purification	and	detection.	
In	this	way	we	obtained	a	well-defined	conjugate	with	only	one	AF488	molecule	(Fig.	1A).	
This	final	compound	was	referred	to	as	R3VQ-S-AF488.	The	pI	of	R3VQ-SH	and	R3VQ-S-
AF488	were	analyzed	by	NEPHGE	using	IEF	3-10	gel.	The	pI	of	R3VQ-SH	was	between	8.3	and	
9.5	(Fig.	1B),	similar	to	that	of	R3VQ.	The	addition	of	maleimido-AF488	to	R3VQ-SH	
decreased	its	pI	to	ca.	8.3	(Fig.	1B).	The	two	bands	on	IEF	gel	indicate	the	presence	of	two	
isoforms	for	both	R3VQ-SH	and	R3VQ-S-AF488.	
3.1.2. Immunodetection	of	Aβ	brain	lesions	in	mice	and	in	human	brain	
sections	
VHH	immunohistochemistry	(IHC)	was	performed	in	plaques-enriched	AD	tissues	(isocortical	
samples)	and	in	PS2APP	mice	[24,25]	harboring	amyloid	deposits.	R3VQ	showed	excellent	
sensitivity	and	selectivity	in	detecting	extracellular	amyloid	plaques	and	cerebral	amyloid	
angiopathy	(CAA),	both	on	human	and	mouse	paraffin	sections	pre-treated	with	formic	acid	
[28]	(Fig.	2A-B).	Immunodetection	of	amyloid	plaques	was	also	possible	on	fresh	brain	
tissues	from	AD	patients	without	the	use	of	any	antigen	retrieval	pre-treatement	(Fig.	S1B).	
Double	labeling	performed	on	mouse	sections	using	4G8	(as	a	gold-standard	anti-Aβ	
monoclonal	antibody	(mAb))	and	R3VQ	showed	a	very	good	colocalization	of	the	two	
antibodies	(Fig.	2C).	Comparison	of	amyloid	loads	detected	by	R3VQ	and	4G8	showed	
excellent	correlation	between	the	results	obtained	with	the	two	antibodies	(Fig.	S1C).	No	
labeling	was	observed	following	R3VQ	IHC	on	tissues	from	age-matched	wild	type	C57Bl/6	
mice	(Fig.	S1D).	The	R3VE	variant	showed	similar	immunodetection	to	R3VQ	on	PS2APP	
mouse	tissue	(Fig.	S1E).		
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Fig.	2.	Immunohistochemical	characterization	of	VHH	R3VQ	as	a	specific	probe	for	
labeling	of	amyloid	deposits.	
R3VQ	show	similar	sensitivity	and	selectivity	to	reference	antibody	4G8	for	detecting	
amyloid	plaques	and	cerebral	amyloid	angiopathy	(CAA)	on	both	human	AD	(A)	and	PS2APP	
mouse	(B)	paraffin	sections.	Double	immunofluorescent	staining	of	4G8	(green)	and	R3VQ	
(red)	on	brain	tissue	from	a	young	PS2APP	mouse	confirmed	the	high	specificity	of	R3VQ	(C).	
	
3.2. In	vivo	labeling	of	Aβ-positive	lesions	
3.2.1. Diffusion	of	R3VQ	after	stereotaxic	brain	injection	
To	test	the	ability	of	R3VQ	to	diffuse	in	the	brain	and	to	label	in	vivo	amyloid	plaques,	six	
micrograms	of	R3VQ	was	stereotaxically	injected	into	the	cortex	of	12-month	old	PS2APP	
mice	(n=2).	The	mice	were	sacrificed	2	hours	after	injection.	IHC	revealed	that	R3VQ	diffused	
in	a	large	spherical	region	(approximatively	3	mm	diameter)	and	amyloid	plaques	were	
detected	in	this	volume	(Fig.	S2A).	The	results	demonstrate	a	good	ability	of	R3VQ	to	diffuse	
through	living	tissue	and	to	label	Aβ	lesions	quite	rapidly	(<	2	hours).	To	summarize,	the	VHH	
R3VQ	was	able	to	diffuse	in	the	brain	and	specifically	target	amyloid	plaques	in	vivo.	
3.2.2. BBB	transit	and	diffusion	of	R3VQ	after	intravenous	injection		
To	investigate	if	R3VQ-S-AF488	crossed	the	BBB,	a	50-mg/kg	dose	was	injected	iv	into	two	
12-month-old	PS2APP	mice.	In	parallel,	two	age-matched	PS2APP	were	injected	with	PBS	
(negative	controls)	or	with	AlexaFluor	488	conjugated	anti-Aβ	mAb	4G8	(4G8-S-AF488;	50	
mg/kg)	as	controls	for	BBB	passage	of	standard	immunoglobulins.	Four	hours	after	injection,	
the	mice	were	sacrificed	and	paraffin	brain	sections	were	prepared.	In	R3VQ-S-AF488	
injected	mice	immunostaining	using	anti-His	mAb	showed	extensive	plaque	labeling	
throughout	the	brain.	This	demonstrates	that	the	VHH	conjugate	was	able	to	cross	the	BBB,	
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diffuse	widely	in	the	living	brain	and	label	its	target.	In	contrast,	no	staining	was	found	in	
mice	injected	with	PBS	(Fig.	S3)	and	only	few	plaques	in	restricted	brain	regions	were	
detected	following	4G8-S-AF488	injections,	underlining	very	limited	BBB	permeability	for	
regular	immunoglobulins	(Fig.	S3).	
3.2.3. Real-time	imaging	of	R3VQ	after	intravenous	injection			
A	50-mg/kg	dose	of	R3VQ-S-AF488	was	injected	in	the	tail	vein	of	a	one-year-old	PS2APP	
mouse.	The	conjugate	extravasation	and	diffusion	in	the	brain	was	recorded	for	4	hours	post	
injection	using	two-photon	microscopy	of	a	cortical	brain	window	(from	surface	to	360	µm	
deep).	Fig.	3A	displays	in	vivo	imaging	of	the	same	region	of	interest	at	1	and	30	min	post-
injection	of	R3VQ-S-AF488.	A	few	seconds	after	iv	injection,	strong	labeling	of	arborescent	
vessels	was	observed.	After	20	min	only	few	capillary	vessels	were	still	labeled.	This	
suggested	a	short	half-life	(10-20	min)	of	conjugated	VHH	in	the	blood	circulation	[29].	
Shortly	after	injection	a	green	fluorescent	“cloud”	formed	and	spread	in	the	parenchymal	
space,	reminiscent	of	the	diffusion	observed	following	stereotaxic	injection	of	R3VQ	(Fig.	
S2A).	Thirty	minutes	after	injection,	both	amyloid	plaques	and	vascular	Aβ	(CAA)	began	to	be	
visualized.	In	vivo	labeling	of	Aβ	deposition	in	plaques	and	vessels	remained	up	to	four	hours	
after	injection	(Fig.	3B	and	Video	S1),	suggesting	a	half-life	of	R3VQ-S-AF488	extending	over	
several	hours	in	the	brain.	Four	hours	after	the	intravenous	injection	of	R3VQ-S-AF488,	the	
brain	was	harvested	and	paraffin	sections	were	prepared.		
Using	anti-His	mAb,	immunodetection	of	amyloid	plaques	by	R3VQ-S-AF488	was	observed	
throughout	the	entire	brain	with	an	accompanying	background	signal	which	could	
correspond	to	the	diffusion	halo	of	the	VHH	(Fig.	3C).	Additional	experiments	were	
performed	with	a	lower	dose	of	R3VQ-S-AF488	(10	mg/kg)	and	in	vivo	detection	of	Aβ	
deposition	was	observed	but	with	decreased	intensity.	These	results	demonstrated	that	
R3VQ	brain	penetration	and	its	ability	to	label	brain	Aβ	lesions	were	dose-dependent,	an	
observation	which	was	also	confirmed	by	IHC	(Fig.	3D).	
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Fig.	3.	In	vivo	imaging	of	VHH	R3VQ-S-AF488	using	two-photon	microscopy.		
(A,	B)	In	vivo	imaging	in	the	brain	after	iv	injection	of	R3VQ-S-AF488	in	a	one-year-old	
PS2APP	mouse.	Maximum	intensity	projection	with	a	projected	volume	extending	360μm	
deep	from	the	surface	of	the	cortex.	T0	represents	the	baseline	imaging	before	iv	injection.	
Yellow	arrowheads	indicate	vascular	Aβ	and	white	arrowheads	indicate	parenchymal	Aβ	
deposits.	(B)	was	obtained	four	hours	after	injection.	(C)	Ex	vivo	detection	of	amyloid	
plaques	in	PS2APP	mouse	that	received	iv	injection	of	R3VQ-S-AF488	four	hours	before	
sacrifice.	Immunostaining	of	amyloid	plaques	by	extrinsic	R3VQ	was	observed	throughout	
the	brain.	The	right	image	showed	a	magnified	view	from	the	left	image.	(D)	Comparison	of	
immunostaining	of	amyloid	plaques	in	PS2APP	mice	receiving	iv	injections	of	either	10	mg/kg	
or	50	mg/kg	of	R3VQ-S-AF488.	
	
The	basic	pI	of	VHHs	has	been	proposed	to	be	an	important	parameter	predicting	their	
ability	to	transmigrate	across	the	BBB	[18].	R3VE-S-AF488	conjugate	was	prepared	with	a	pI	
of	ca.	7.5	(Fig.	S4A,	B).	A	10	mg/kg	dose	of	R3VE-S-AF488	was	iv	injected	in	a	one-year-old	
PS2APP	mouse.	Forty-five	minutes	after	injection,	only	cerebral	amyloid	angiopathy	was	
	
A 
B C 
D 
	
50µm 
500µm 
	
100µm 100µm 
	 11	
shown	without	signs	of	extravasation	or	labeling	of	amyloid	plaques	(Fig.	S4C),	supporting	
the	hypothesis	that	the	positive	charges	present	on	the	surface	of	VHHs	play	a	critical	role	
for	brain	penetration	of	these	antibodies	across	the	BBB.	
Finally,	R3VQ-S-AF488	at	50	mg/kg	was	intravenously	injected	in	a	wild-type	mouse.	Except	
for	initial	blood	vessel	labeling,	no	specific	in	vivo	staining	in	the	brain	parenchyma	was	
observed	using	two-photon	microscopy	imaging.	A	fluorescent	cloud	appeared	1	hour	after	
injection	(suggesting	presence	of	unbound	R3VQ-S-AF488	in	the	brain)	but	then	rapidly	
vanished	(Fig.	S5).	These	data	indicate	that	R3VQ-S-AF488	crosses	the	BBB	in	wild-type	mice	
but	is	not	retained	in	the	absence	of	amyloid	plaques.		
	
In	summary,	using	two-photon	microscopy	after	intravenous	injection	of	R3VQ-S-AF488,	we	
demonstrated	the	ability	of	the	VHH	R3VQ	to	cross	the	BBB,	to	reach	its	extracellular	
cerebral	target	and	to	transport	fluorescent	probes	across	the	BBB,	allowing	its	real-time	
visualization.		
3.3. Selection	and	characterization	of	a	VHH	recognizing	
intracellular	targets	
3.3.1. Generation	and	engineering	of	A2		
One	alpaca	was	immunized	with	AD	phospho-tau	(pTau)	enriched	brain	extracts	and	a	
second	alpaca	was	immunized	with	a	mono-phosphorylated	peptide	derived	from	the	C-
terminus	of	the	tau	protein	(pS422	peptide)	coupled	to	the	KLH	protein.	The	sera	of	
immunized	alpacas	recognized	both	pTau	and	non-phosphorylated	tau.	The	immunized	
animals	generated	2	phage-VHH	libraries	of	about	3x108	clones	each.	In	order	to	expand	the	
diversity	of	VHHs,	a	pooled	library	from	these	two	animals	was	used	for	panning	
experiments	by	Phage	Display.	After	3	panning	cycles	with	pTau	protein,	one	clone	was	
found	to	bind	specifically	to	pTau	and	was	referred	to	as	A2.	C-terminally	His	tagged	A2	was	
produced	as	described	above	for	R3VQ	VHH	(yield	5	mg/l	of	culture).	Only	one	band	was	
observed	by	SDS-PAGE	(Fig.	4A).	Analysis	by	IEF-NEPHGE	showed	that	the	pI	of	A2	was	higher	
than	9.5	(Fig.	4B).	ELISA	was	performed	on	pTau	and	pS422	peptide	coupled	to	ovalbumin.	
pTau	corresponded	to	the	full-length	tau	protein	phosphorylated	at	multiple	sites	including	
S422.	A2	bound	to	both	full-length	pTau	protein	and	the	pS422-containing	peptide.	Lack	of	
binding	to	non-phosphorylated-tau	demonstrated	that	A2	was	specific	for	a	phosphorylated	
epitope	(Fig.	4C).		
For	the	purpose	of	in	vivo	analysis,	an	A2-SH	variant	was	prepared	and	conjugated	to	AF488	
as	previously	described	for	R3VQ-S-AF488	(see	above).	The	pI	of	A2-SH	and	A2-S-AF488	was	
between	9.5	and	10.7.	The	addition	of	maleimido-AF488	to	A2-SH	slightly	decreased	the	pI	
of	A2-SH	as	already	observed	with	R3VQ-S-AF488	(Fig.	4B).	
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Fig.	4.	Biochemical	characterization	of	VHH	A2	and	its	variants.		
(A)	Protein	analysis	of	VHH	A2,	A2-SH	and	A2-S-AF488	by	SDS-PAGE.	(B)	Determination	of	pI	
of	A2	variants	by	NEPHGE	on	3-10	IEF	gel.	(C)	Binding	of	A2	to	phospho-tau	(pTau),	non-
phosphorylated	tau	and	Ova-pS422	peptide.	
	
3.3.2. Immunodetection	of	tau	brain	lesions	in	mice	and	in	human	brain	
sections	
VHH	A2	allowed	detection	of	intracellular	neurofibrillary	tangle-like	structures	in	Tg4510	
mouse	brain	tissues	using	paraffin	sections	with	or	without	any	antigen	retrieval	
pretreatment	(Fig.	5B).	Specific	staining	of	neurofibrillary	tau	inclusions	with	A2	was	also	
readily	obtained	on	free	floating	sections	from	Tg4510	mice	(Fig.	S6A).	Comparable	staining	
was	observed	using	the	reference	anti-pTau	AT8	mAb	[30].	No	labeling	was	noted	with	
tissues	from	age-matched	wild	type	mice	(Fig.	S6A).	Double	labeling	performed	on	mouse	
sections	using	the	A2	and	reference	antibody	AT8	showed	strong	colocalization	of	the	two	
immunostainings	(Fig.	5C).	The	load	of	tau lesions	detected	by	A2	and	AT8	antibodies	were	
highly	correlated	underlining	similar	sensitivity-specificity	profiles	(Fig.	S6B).	
Using	paraffin-fixed	AD	brain	sections,	VHH	A2	detected	neurofibrillary	tau	tangles	in	
neuronal	soma,	tortuous	fibers	and	dystrophic	neurites	was	also	obtained	in	(Fig.	5A).	
Additional	experiments	(Fig.	S7)	showed	that	VHH	A2	also	recognized	tau-positive	lesions	
from	other	tauopathies	e.g.	glial	inclusions	in	tissues	from	patients	with	fronto-temporal	
dementia	(oligodendroglial	coiled	bodies)	or	with	progressive	supranuclear	palsy	(astrocytic	
tufts).		
To	our	knowledge,	this	is	the	first	VHH	that	has	been	shown	to	detect	tau	lesions	in	both	tau	
transgenic	mouse	and	human	tauopathy	brain	tissues.	
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Fig.	5.	Immunohistochemical	characterization	of	VHH	A2	as	a	specific	probe	for	
labeling	neurofibrillary	tangles.	
A2	shows	similar	sensitivity	and	selectivity	to	AT8	in	detecting	NFTs	on	both	human	AD	(A)	
and	Tg4510	mouse	(B)	brain	sections.	Double	immunofluorescence	staining	of	AT8	and	A2	
on	Tg4510	mouse	tissue	confirmed	the	high	specificity	of	A2	(C).	
	
3.4. In	vivo	labeling	of	tau-positive	lesions:	
3.4.1. Diffusion	of	A2	after	stereotaxic	brain	injection	
To	test	the	ability	of	A2	to	immunolabel	tau	lesions	in	vivo,	A2	was	stereotaxically	injected	
into	the	cortex	of	10-month-old	Tg4510	mice.	The	mice	were	sacrificed	2	hours	after	
injection.	IHC	revealed	that	A2	had	diffused	throughout	the	entire	brain	and	bound	to	pTau	
aggregates	in	numerous	cortical	and	subcortical	regions	(Fig.	S2B).		
3.4.2. BBB	transit	and	diffusion	of	A2	after	intravenous	injection		
To	investigate	if	A2-S-AF488	crosses	the	BBB,	the	same	systematic	approach	as	implemented	
for	R3VQ-S-AF488	(see	above)	was	applied.	A	10	mg/kg	dose	of	A2-S-AF488	was	injected	iv	in	
two	8-month-old	Tg4510	mice	that	were	sacrificed	4	hours	later.	Immunostaining	using	anti-
A2	polyclonal	antibody	showed	binding	to	a	large	number	of	NFT-like	structures	in	the	brain,	
demonstrating	that	A2-S-AF488	crossed	the	BBB,	diffused	extensively	throughout	the	brain	
in	vivo	and	labeled	pTau	aggregates.	By	contrast,	no	staining	was	found	in	the	mice	injected	
with	PBS	or	with	a	conventional	antibody	specific	for	pTau	(Fig.	S3).		
3.4.3. Real-time	imaging	A2	after	intravenous	injection		
VHH	A2-S-AF488	(10	mg/kg)	was	injected	in	the	tail	vein	of	Tg4510	mice.	A2-S-AF488	
extravasation	and	diffusion	in	the	brain	was	monitored	for	4	hours	post	injection	using	two-
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photon	microscopy	imaging	of	the	cortical	surface	up	to	350	µm	deep.	Immediately	after	iv	
injection,	cerebral	blood	vessels	showed	strong	fluorescence,	as	observed	for	R3VQ.	
Identification	of	NFT-like	structures	was	possible	2	hours	after	injection	(Fig.	6A).	A	
persistent	and	specific	labeling	of	NFTs	was	observed	even	4	hours	after	injection	(Fig.	6B)	
and	the	3D	reconstruction	of	the	immuno-detected	objects	revealed	the	standard	flame-
shaped	morphology	of	tangles	(Video	S2).	Four	hours	after	injection,	the	mice	were	
sacrificed,	immunohistochemistry	was	performed	using	anti-A2	polyclonal	antibody	to	
demonstrate	the	presence	of	A2-S-AF488	in	the	brain.	Extensive	tau	immunostaining	
throughout	the	brain	was	also	confirmed	in	postmortem	tissue	(Fig.	6C).		
	
	
Fig.	6.	In	vivo	imaging	of	VHH	A2-S-AF488	using	two-photon	microscopy.	
(A)	Maximum	intensity	projection	of	fluorescence	in	an	8-month-old	Tg4510	mouse	at	
different	timepoints	after	iv	injection	of	A2-S-AF488	at	10	mg/kg.	Whereas	only	faint	non-
specific	signal	could	be	detected	before	iv	injection	(T0),	a	strong	staining	of	arborescent	
vessels	was	observed	a	few	seconds	after	iv	injection.	Specific	labeling	of	NFTs	(white	arrows)	
occurred	only	after	120	min,	with	a	maximum	intensity	after	180	min.	(B)	Specific	staining	of	
NFTs	was	observed	4	hours	post	injection.	(C)	Ex	vivo	detection	of	NFT	labeling	by	extrinsic	
A2	VHH	on	brain	sections	obtained	from	Tg4510	mice	four	hours	after	iv	injection	of	A2-S-
AF488.	The	image	on	the	bottom	left	and	the	image	on	the	right	showed	magnified	views	in	
the	cortex	and	CA3.	
	
In	summary,	VHH	A2-S-AF488	efficiently	crossed	the	BBB	and	penetrated	into	neurons	to	
reach	its	cytoplasmic	target.	As	for	in	vivo	R3VQ	experiments,	target	labeling	was	visible	four	
hours	after	administration	demonstrating	slow	turnover	of	target-associated	VHHs	in	the	
brain.	
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4. DISCUSSION	
4.1. VHHs	bind	to	both	extracellular	and	intracellular	brain	targets	
VHHs	were	generated	to	Aβ42	and	phospho-tau	(R3VQ	and	A2,	respectively).	Their	
specificities	were	biochemically	assessed	and	then	confirmed	by	immunohistochemistry	on	
both	human	and	AD	transgenic	mouse	brain	tissues.	To	the	best	of	our	knowledge,	the	VHH	
A2	presented	here	is	the	first	engineered	VHH	capable	of	immunodetecting	AD-associated		
intraneuronal	NFT	pathology.	
By	means	of	stereotaxic	injection	we	then	confirmed	the	ability	of	R3VQ	and	A2	to	label	their	
targets	in	vivo	after	rapid	diffusion	in	brain	tissue,	a	result	that	may	be	explained	by	the	
small	size	of	the	constructs	[13].	Notably,	the	antigen	binding	properties	of	both	VHHs	were	
preserved	after	conjugation	with	AlexaFluor	488,	therefore	opening	up	opportunities	to	use	
labeled	VHHs	for	in	vivo	imaging.	
4.2. VHHs	cross	the	BBB	and	efficiently	diffuse	in	the	brain	
A	few	VHHs	have	been	shown	to	cross	the	BBB	by	receptor-mediated	transcytosis	[31,32].	
We	have	previously	shown	that	VHH	E9	with	basic	pI	was	able	to	passively	cross	the	BBB,	
diffuse	in	the	brain	parenchyma	and	label	astrocytes	in	vivo	[18].		
An	anti-Aβ	VHH	(pa2H)	was	previously	reported	to	cross	the	BBB	in	vivo	[29].	However	pa2H	
brain	uptake	was	too	low	to	allow	in	vivo	imaging.	More	recently	the	same	research	group	
designed	a	glutathione	PEGylated	liposomal	encapsulation	system	to	enhance	the	delivery	of	
pa2H	across	the	BBB	[33].	SPECT	imaging	performed	in	this	study	did	not	however	allow	the	
visualization	of	pa2H	brain	penetration.	In	our	study	plaques	and	NFTs	were	detected	in	vivo	
after	a	single	iv	injection	of	fluorescent	R3VQ	and	A2	respectively,	confirming	they	readily	
cross	the	BBB	and	have	exquisite	sensitivity	of	the	engineered	VHHs.	The	presence	of	VHHs	
throughout	the	brain	was	subsequently	confirmed	by	immunohistochemistry.	Labeling	of	
amyloid	plaques	and	NFTs	by	R3VQ	and	A2	respectively	was	detectable	with	high	signal	
intensity	up	to	4	hours	post-injection,	suggesting	a	long	half-life	of	VHHs	in	the	brain,	at	least	
when	bound	to	target.	Indeed,	Nabuurs	and	collaborators	indicated	that	their	anti-Aβ	VHH	
remained	detectable	in	the	brain	for	at	least	24	hours	post-injection	[29].		
R3VQ-S-AF488	demonstrated	rapid	diffusion	(0.5-1	h	post-injection)	throughout	the	brain	of	
PS2APP	mice	and	showed	high	specificity	for	Aβ	deposits	in	both	parenchymal	(Aβ	plaques)	
and	vascular	spaces	(CAA).	In	the	Tg4510	mice	receiving	iv	injection	of	A2-S-AF488,	the	
specific	staining	of	NFTs	was	observed	2h	post-injection,	much	later	than	with	R3VQ-S-
AF488,	probably	because	A2-S-AF488	had	to	cross	two	barriers:	the	BBB	and	the	cell	
membrane	of	neurons	containing	NFTs.			
	
Traumatic	uncontrolled	BBB	opening	during	the	two-photon	imaging	procedure	related	to	
local	brain	bleeding	due	to	craniotomy	could	have	explained	our	results,	however	such	a	
possibility	is	implausible.	First	we	observed	that	both	R3VQ	and	A2	VHHs	were	distributed	
throughout	the	whole	brain	following	iv	injection	and	not	only	in	the	vicinity	of	the	cranial	
window	as	would	be	the	case	if	there	was	local	bleeding.	Second,	four	hours	after	iv	injection	
into	transgenic	mice	without	any	cranial	surgery	both	fluorescent	VHHs	labeled	their	
respective	targets	in	the	brain.		
It	remains	possible	that	the	passage	of	VHHs	across	the	BBB	resulted	from	a	“naturally-
compromised”	barrier	in	the	transgenic	mice.	Indeed,	during	normal	aging,	the	permeability	
of	the	BBB	increases,	and	disruption	of	the	BBB	occurs	in	a	number	of	neurological	disorders,	
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including	AD	[34,35].	A	recent	study	indicates	however	a	lack	of	BBB	permeability	in	the	
PS2APP	transgenic	line	we	used	for	R3VQ	imaging	[36],	even	at	the	oldest	ages.	Evidence	of	
BBB	leakage	has	been	reported	in	Tg4510	mice	but	starting	at	9	months	of	age	[37]	however	
we	conducted	in	vivo	imaging	in	younger	animals.	We	confirmed	the	absence	of	BBB	leakage	
in	the	two	models	we	used	by	demonstrating	that	conventional	immunoglobulin	specific	for	
the	targeted	antigens	did	not	significantly	penetrate	into	the	CNS	following	iv	injection.		
Finally,	it	could	be	argued	that	high	VHH	concentrations	(from	10	to	50	mg/kg)	induce	a	
transient	disruption	of	the	BBB	and	an	extravasation	of	the	VHH.	However,	our	previous	
study	using	an	Evans	Blue	dye	exclusion	assay	showed	that	VHHs	do	not	compromise	the	
BBB	even	using	VHH	at	very	high	concentration	(133	mg/kg,	i.e.	4	mg	for	an	adult	mouse)	
[18].	
To	summarize	we	showed	that	both	R3VQ	and	A2	can	cross	the	BBB	after	peripheral	
administration	and	bind	to	extracellular	(plaques)	and	intracellular	(tangles)	brain	targets.	
The	factors	influencing	VHH	transit	across	the	BBB	are	poorly	understood.	The	molecular	size	
of	VHHs	was	demonstrated	to	be	an	important	parameter	for	their	brain	penetration	with	a	
rate	of	passage	decreased	for	large-sized	VHH	constructs:	dimers	of	VHH	(molecular	weight	
of	28kDa)	or	a	VHH	fused	to	EGFP	(molecular	weight	of	40	kDa)	[18].	The	molecular	weight	of	
the	VHH-S-AF488	used	in	the	present	study	was	slightly	increased	by	the	addition	of	a	
fluorophore	(+	1	kDa),	but	this	modification	did	not	affect	their	apparent	brain	penetration.	
Basic	pI	also	appears	to	be	an	important	parameter	since	a	VHH	variant	with	a	near-neutral	
pI	(R3VE)	showed	only	limited	brain	penetration.	In	our	previous	study	using	an	anti-GFAP	
VHH	we	showed	that	BBB	crossing	was	not	energy-dependent,	suggesting	active	transport	is	
not	involved	[18].	The	transmigration	of	basic	VHHs	through	the	BBB	probably	occurs	by	
adsorptive-mediated	endocytosis	initiated	by	non-specific,	charge-based	interactions	with	
proteins	at	the	endothelial	cell	surface	[38–41].	Recent	studies	demonstrated	that	proteins	
with	high	net	positive	charge	have	indeed	the	ability	to	penetrate	mammalian	cells	and	
deliver	macromolecules	into	cells	in	vitro	and	in	vivo	[42,43].	Understanding	the	precise	
mechanism	of	VHH	BBB	passage	will	be	important	for	optimizing	efficient	targeted	probes	in	
the	future.	
4.3. VHH	potential	for	AD	diagnosis	
	
Until	now	the	development	of	imaging	markers	for	AD	brain	lesions	has	focused	on	PET	
ligands	[44–50].	However	PET	imaging	suffers	from	numerous	drawbacks,	namely,	low	
spatial	resolution,	exposure	to	radiation,	limited	availability	and	high	cost.	Conversely,	MRI	
provides	information	with	high	spatial	resolution,	does	not	rely	on	ionizing	radiations	and	is	
widely	available	for	clinical	use.	Previous	attempts	have	been	made	to	use	MR	contrast	
agents	for	visualizing	amyloid	deposits	in	AD	mouse	models.	However	these	studies	relied	on	
artificial	BBB	opening	by	ultrasound	[7,8]	or	BBB	permeability	enhancers	such	as	mannitol	
[9].	With	the	goal	of	developing	a	more	physiological	approach	we	are	currently	improving	a	
method	for	site-specifically	conjugating	VHHs	to	paramagnetic	gadolinium.	The	VHHs	
described	in	the	present	work	could	be	conjugated	with	gadolinium	to	provide	a	novel	MR	
imaging	agents	for	AD.		
An	important	parameter	to	consider	is	the	potential	immunogenicity	of	VHHs	in	human	
patients,	if	they	would	be	applied	for	diagnosis	and/or	follow-up	of	the	patients	with	AD.	
VHHs	actually	have	multiple	advantages	for	diagnostic	applications,	such	as	small	size,	high	
stability,	fast	blood	clearance	[12].	Also	VHH	sequences	share	high	homology	with	human	VH	
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sequences[51].	All	these	characteristics	predict	low	immunogenicity	of	VHHs.	Indeed,	
previous	studies	underlined	that	VHHs	did	not	induce	an	immunogenic	reaction	after	
injection	in	mice	[52–54]	and	a	lower	risk	of	immunogenicity	was	expected	in	humans.	
Moreover,	VHHs	can	be	humanized	without	loss	of	their	stability,	affinity	and	specificity	
[55,56],	and	numerous	VHHs	are	currently	in	clinical	development	
(http://www.ablynx.com/rd-portfolio/overview/).	
	
4.4. Conclusions	
We	describe	novel	VHHs	that	could	be	potentially	used	as	in	vivo	imaging	agents	able	to	
detect	brain	lesions	observed	in	human	diseases,	e.g.	Alzheimer’s	disease.	VHH	R3VQ	binds	
to	brain	Aβ	deposits	and	VHH	A2	recognizes	neuronal	pathological	tau	inclusions.	VHHs	are	
able	to	penetrate	the	brain	more	efficiently	than	conventional	IgGs	and	they	can	be	readily	
site-specifically	modified	for	in	vivo	imaging	of	neurodegenerative	diseases	with	extracellular	
or	intracellular	misfolded	protein	aggregates.	
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